Compare Macy's Inc (M) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs BIO-TECHNE Corp — how do they compare? Macy's Inc trades at $22.76 (market cap $5.95B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and BIO-TECHNE Corp for 63 Days on average.
| M | TECH | |
|---|---|---|
Market Cap | $5.95B | $11.36B |
Volume | 6,030,644 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $72.61 |
52-Week Low | $16.51 | $43.31 |
Typical Hold Time | 58 Days | 63 Days |
Enterprise Value | $9.75B | $11.39B |
Dividend Yield | 3.36% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's stock trades at $22.61, down 0.79% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and a 'Bold New Chapter' strategy driving digital transformation. Valuation metrics appear attractive with P/E of 8.35 and P/S of 0.27, while profitability shows recovery with ROE of 15.99% and net margin improvement to 3.29%.
The outlook remains cautiously optimistic with analyst consensus at $24.25 representing 7% upside potential. Key opportunities include digital growth initiatives and dividend sustainability, while risks involve retail sector headwinds and uneven quarterly performance. The stock offers value characteristics with turnaround potential, supported by improved cash flow generation and balance sheet strength.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
